Psoriatic Arthritis
News
Low infliximab start dose appears effective in psoriatic arthritis
Key clinical point: Most patients with psoriatic arthritis fare well on a lower than recommended starting dose.Major finding: Median starting...
Conference Coverage
Treat to target shows durable improvements in psoriatic arthritis
News
Brodalumab outperformed placebo for psoriatic arthritis
Key clinical point: Interleukin-17 receptor A is a potential treatment target in psoriatic arthritis patients, whether or not they have received...
Conference Coverage
Apremilast appears to have multiple, lasting benefits in psoriatic arthritis
Key clinical point: Apremilast maintained its efficacy and safety profile through 1 year of treatment.Major finding: At 52 weeks, 55%-63% of...
News
FDA approves PDE-4 inhibitor for treating psoriatic arthritis
News
Gut-joint connection promising in psoriatic arthritis
News
Shift in approach needed for managing inflammatory arthritis in pregnancy
Conference Coverage
Apremilast’s positive study results made it the talk of ACR 2013
Major finding: After 16 weeks of treatment, the investigational drug apremilast achieved an ACR20 response of 29.2% at 20 mg twice daily as first-...
Conference Coverage
Treat-to-target approach for psoriatic arthritis found beneficial
Major finding: At 48 weeks, a higher proportion of psoriatic arthritis patients in the intensive management group achieved ACR70, compared with...
News
Ustekinumab approved for psoriatic arthritis
Conference Coverage
Apremilast effects sustained at 1 year in psoriatic arthritis
Major finding: ACR 20 response at 1 year was 57%-63% for patients given apremilast.Data source: PALACE 1, a 504-patient, phase III, multicenter,...